{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:59:08Z","timestamp":1780919948048,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>We aim to explore the association between NSAIDs consumption, Symptomatic Slow Action Drugs for Osteoarthritis (SYSADOA), analgesics, and antiplatelet drugs, and decline in renal function by estimated Glomerular Filtration Rate (eGFR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a case-control study using the SIDIAP database in Catalonia. We considered defined cases, patients with an eGFR value\u2009\u2264\u200945\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> in the period 2010\u20132015 with a previous eGFR value\u2009\u2265\u200960, and no eGFR\u2009\u2265\u200960 after this period. Controls had an eGFR\u2009\u2265\u200960 with no previous eGFR\u2009&lt;\u200960. Five controls were selected for each case, matched by sex, age, index date, Diabetes Mellitus and Hypertension. We estimated Odds Ratios (OR, 95% Confidence Intervals) of decline in renal function for drugs group adjusting with logistic regression models, by consumption measured in DDD. There were <jats:italic>n<\/jats:italic>\u2009=\u200918,905 cases and <jats:italic>n<\/jats:italic>\u2009=\u200994,456 controls. The mean age was 77 years, 59% were women. The multivariate adjusted model showed a low risk for eGFR decline for NSAIDs (0.92;0.88\u20130.97), SYSADOA (0.87;0.83\u20130.91) and acetaminophen (0.84;0.79\u20130.89), and an high risk for metamizole (1.07;1.03\u20131.12), and antiplatelet drugs (1.07;1.03\u20131.11). The low risk in NSAIDs was limited to propionic acid derivatives (0.92;0.88\u20130.96), whereas an high risk was observed for high doses in both acetic acid derivatives (1.09;1.03\u20131.15) and Coxibs (1.19;1.08\u20131.30). Medium and high use of major opioids shows a high risk (1.15;1.03\u20131.29). Triflusal showed high risk at medium (1.23;1.02\u20131.48) and high use (1.68;1.40\u20132.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We observed a decline in renal function associated with metamizole and antiplatelet agent, especially triflusal, and with high use of acetic acid derivates, Coxibs, and major opioids. Further studies are necessary to confirm these results.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-024-00771-5","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T10:02:07Z","timestamp":1724839327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["NSAIDs, analgesics, antiplatelet drugs, and decline in renal function: a retrospective case-control study with SIDIAP database"],"prefix":"10.1186","volume":"25","author":[{"given":"Sara","family":"Bonet-Monn\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Vedia","family":"Urgell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Jos\u00e9 P\u00e9rez","family":"S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol Cunillera","family":"Puertol\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Baena-D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Orive","family":"Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi Rodriguez","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betlem Salvador","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Morros","family":"Pedr\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"4","key":"771_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.pop.2020.08.001","volume":"47","author":"C Charles","year":"2020","unstructured":"Charles C, Ferris AH. Chronic kidney disease. Prim Care. 2020;47(4):585\u201395. https:\/\/doi.org\/10.1016\/j.pop.2020.08.001.","journal-title":"Prim Care"},{"issue":"6","key":"771_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.nefro.2018.04.004","volume":"38","author":"M Gorostidi","year":"2018","unstructured":"Gorostidi M, S\u00e1nchez-Mart\u00ednez M, Ruilope LM, Graciani A, de la Cruz JJ, Santamar\u00eda R, Del Pino MD, Guallar-Castill\u00f3n P, de \u00c1lvaro F, Rodr\u00edguez-Artalejo F, Banegas JR. Chronic kidney disease in Spain: prevalence and impact of accumulation of cardiovascular risk factors. Nefrolog\u00eda. 2018;38(6):606\u201315. https:\/\/doi.org\/10.1016\/j.nefro.2018.04.004.","journal-title":"Nefrolog\u00eda"},{"issue":"1","key":"771_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3265\/Nefrologia.pre2009.Dic.5732","volume":"30","author":"A Otero","year":"2010","unstructured":"Otero A, de Francisco A, Gayoso P, Garc\u00eda F, EPIRCE Study Group. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia. 2010;30(1):78\u201386. https:\/\/doi.org\/10.3265\/Nefrologia.pre2009.Dic.5732.","journal-title":"Nefrologia"},{"key":"771_CR4","unstructured":"Organitzaci\u00f3 Catalana de Trasplantaments (OCATT). Registre de malalts renals de Catalunya, informe estad\u00edstic 2020. Departament de Salut, Generalitat de Catalunya 2022(35). https:\/\/trasplantaments.gencat.cat\/web\/.content\/minisite\/trasplantament\/registres_activitat\/registre_de_malalts_renals\/arxius\/Informe-RMRC-2020.pdf. Accessed 25 November 2022."},{"issue":"10","key":"771_CR5","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1681\/ASN.2008101097","volume":"20","author":"ME De Broe","year":"2009","unstructured":"De Broe ME, Elseviers MM. Over-the-counter analgesic use. J Am Soc Nephrol. 2009;20(10):2098\u2013103. https:\/\/doi.org\/10.1681\/ASN.2008101097.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"771_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.286.3.315","volume":"286","author":"KM Rexrode","year":"2001","unstructured":"Rexrode KM, Buring JE, Glynn RJ, Stampfer MJ, Youngman LD, Gaziano JM. Analgesic use and renal function in men. JAMA. 2001;286(3):315\u201321. https:\/\/doi.org\/10.1001\/jama.286.3.315.","journal-title":"JAMA"},{"issue":"25","key":"771_CR7","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJM199412223312502","volume":"331","author":"TV Perneger","year":"1994","unstructured":"Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994;331(25):1675\u20139. https:\/\/doi.org\/10.1056\/NEJM199412223312502.","journal-title":"N Engl J Med"},{"issue":"25","key":"771_CR8","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa010323","volume":"345","author":"CM Fored","year":"2001","unstructured":"Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med. 2001;345(25):1801\u20138. https:\/\/doi.org\/10.1056\/NEJMoa010323.","journal-title":"N Engl J Med"},{"issue":"2","key":"771_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/s0272-6386(03)00647-4","volume":"42","author":"T Kurth","year":"2003","unstructured":"Kurth T, Glynn RJ, Walker AM, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis. 2003;42(2):234\u201344. https:\/\/doi.org\/10.1016\/s0272-6386(03)00647-4.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"771_CR10","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/j.1523-1755.2005.00346.x","volume":"67","author":"L Ib\u00e1\u00f1ez","year":"2005","unstructured":"Ib\u00e1\u00f1ez L, Morlans M, Vidal X, Mart\u00ednez MJ, Laporte JR. Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease. Kidney Int. 2005;67(6):2393\u20138. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00346.x.","journal-title":"Kidney Int"},{"issue":"1","key":"771_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1751-7141.2009.00050.x","volume":"13","author":"A Sciahbasi","year":"2010","unstructured":"Sciahbasi A, Arcieri R, Quarto M, et al. Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. Prev Cardiol. 2010;13(1):18\u201322. https:\/\/doi.org\/10.1111\/j.1751-7141.2009.00050.x.","journal-title":"Prev Cardiol"},{"issue":"14","key":"771_CR12","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/archinte.164.14.1519","volume":"164","author":"GC Curhan","year":"2004","unstructured":"Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004;164(14):1519\u201324. https:\/\/doi.org\/10.1001\/archinte.164.14.1519.","journal-title":"Arch Intern Med"},{"issue":"3","key":"771_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.amjmed.2006.02.015","volume":"120","author":"K Gooch","year":"2007","unstructured":"Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(3):280.e1-280.e2807. https:\/\/doi.org\/10.1016\/j.amjmed.2006.02.015.","journal-title":"Am J Med"},{"issue":"6","key":"771_CR14","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/ndt\/gfn745","volume":"24","author":"M Evans","year":"2009","unstructured":"Evans M, Fored CM, Bellocco R, et al. Acetaminophen, aspirin and progression of advanced chronic kidney disease. Nephrol Dial Transpl. 2009;24(6):1908\u201318. https:\/\/doi.org\/10.1093\/ndt\/gfn745.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"771_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/fampra\/cms086","volume":"30","author":"P Nderitu","year":"2013","unstructured":"Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30(3):247\u201355. https:\/\/doi.org\/10.1093\/fampra\/cms086.","journal-title":"Fam Pract"},{"issue":"4","key":"771_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","volume":"121","author":"AG Johnson","year":"1994","unstructured":"Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121(4):289\u2013300. https:\/\/doi.org\/10.7326\/0003-4819-121-4-199408150-00011.","journal-title":"Ann Intern Med"},{"issue":"13","key":"771_CR17","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1001\/jama.296.13.jrv60015","volume":"296","author":"J Zhang","year":"2006","unstructured":"Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296(13):1619\u201332. https:\/\/doi.org\/10.1001\/jama.296.13.jrv60015.","journal-title":"JAMA"},{"key":"771_CR18","unstructured":"Ficha t\u00e9cnica de etoricoxib. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/81465\/FT_81465.html. Accessed 20 November 2022."},{"issue":"12","key":"771_CR19","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1097\/HJH.0b013e3283310dc9","volume":"27","author":"CC Chan","year":"2009","unstructured":"Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009;27(12):2332\u201341. https:\/\/doi.org\/10.1097\/HJH.0b013e3283310dc9.","journal-title":"J Hypertens"},{"issue":"5","key":"771_CR20","doi-asserted-by":"publisher","first-page":"e105754","DOI":"10.5812\/aapm.105754","volume":"10","author":"S Dolati","year":"2020","unstructured":"Dolati S, Tarighat F, Pashazadeh F, Shahsavarinia K, Gholipouri S, Soleimanpour H. The role of opioids in pain management in elderly patients with chronic kidney disease: a review article. Anesth Pain Med. 2020;10(5):e105754. https:\/\/doi.org\/10.5812\/aapm.105754.","journal-title":"Anesth Pain Med"},{"issue":"21","key":"771_CR21","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1001\/jama.2014.15284","volume":"312","author":"AX Garg","year":"2014","unstructured":"Garg AX, Kurz A, Sessler DI, et al. Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial. JAMA. 2014;312(21):2254\u201364. https:\/\/doi.org\/10.1001\/jama.2014.15284.","journal-title":"JAMA"},{"key":"771_CR22","doi-asserted-by":"publisher","unstructured":"Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2013;2CD008834. https:\/\/doi.org\/10.1002\/14651858.CD008834.pub2.","DOI":"10.1002\/14651858.CD008834.pub2"},{"issue":"1","key":"771_CR23","doi-asserted-by":"publisher","first-page":"e0147635","DOI":"10.1371\/journal.pone.0147635","volume":"11","author":"S Okada","year":"2016","unstructured":"Okada S, Morimoto T, Ogawa H, et al. Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes? JPAD2 cohort study. PLoS ONE. 2016;11(1):e0147635. https:\/\/doi.org\/10.1371\/journal.pone.0147635. Published 2016 Jan 25.","journal-title":"PLoS ONE"},{"key":"771_CR24","doi-asserted-by":"publisher","unstructured":"Nath KA. Platelets, antiplatelet therapy, and diabetic nephropathy. Mayo Clin Proc. 1988;63(1):80\u201385. https:\/\/doi.org\/10.1016\/s0025-6196(12)62670-6","DOI":"10.1016\/s0025-6196(12)62670-6"},{"issue":"2","key":"771_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/003655902753679454","volume":"36","author":"P Khajehdehi","year":"2002","unstructured":"Khajehdehi P, Roozbeh J, Mostafavi H. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scand J Urol Nephrol. 2002;36(2):145\u20138. https:\/\/doi.org\/10.1080\/003655902753679454.","journal-title":"Scand J Urol Nephrol"},{"issue":"7","key":"771_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41581-018-0015-5","volume":"14","author":"MPB Jansen","year":"2018","unstructured":"Jansen MPB, Florquin S, Roelofs JJTH. The role of platelets in acute kidney injury. Nat Rev Nephrol. 2018;14(7):457\u201371. https:\/\/doi.org\/10.1038\/s41581-018-0015-5.","journal-title":"Nat Rev Nephrol"},{"issue":"14","key":"771_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.medcli.2012.01.020","volume":"138","author":"B Bol\u00edbar","year":"2012","unstructured":"Bol\u00edbar B, Fina Avil\u00e9s F, Morros R, et al. Base De Datos SIDIAP: la historia cl\u00ednica informatizada de Atenci\u00f3n primaria como fuente de informaci\u00f3n para la investigaci\u00f3n epidemiol\u00f3gica [SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research]. Med Clin (Barc). 2012;138(14):617\u201321. https:\/\/doi.org\/10.1016\/j.medcli.2012.01.020.","journal-title":"Med Clin (Barc)"},{"issue":"3","key":"771_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.14236\/jhi.v19i3.806","volume":"19","author":"M Garc\u00eda-Gil Mdel","year":"2011","unstructured":"Garc\u00eda-Gil Mdel M, Hermosilla E, Prieto-Alhambra D, et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inf Prim Care. 2011;19(3):135\u201345. https:\/\/doi.org\/10.14236\/jhi.v19i3.806.","journal-title":"Inf Prim Care"},{"key":"771_CR29","unstructured":"International Statistical Classification of Diseases and Related Health Problems 10th Revision. World Health Organitzation. https:\/\/icd.who.int\/browse10\/2019\/en#\/. Accessed 25 November 2022."},{"issue":"11","key":"771_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.7326\/0003-4819-156-6-201203200-00391","volume":"156","author":"A Earley","year":"2012","unstructured":"Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012;156(11):785\u201395. https:\/\/doi.org\/10.7326\/0003-4819-156-6-201203200-00391.","journal-title":"Ann Intern Med"},{"key":"771_CR31","unstructured":"World Health Organization Collaborating Center for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classifica-tion System. http:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 12 August 2021."},{"issue":"12","key":"771_CR32","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2165\/11633470-000000000-00000","volume":"35","author":"J Castellsague","year":"2012","unstructured":"Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127\u201346. https:\/\/doi.org\/10.2165\/11633470-000000000-00000.","journal-title":"Drug Saf"},{"issue":"1","key":"771_CR33","first-page":"63","volume":"35","author":"T Oscanoa-Espinoza","year":"2015","unstructured":"Oscanoa-Espinoza T, Lizaraso-Soto F. Antiinflamatorios no esteroides: seguridad gastrointestinal, cardiovascular y renal [Nonsteroidal antiinflammatory drugs: gastrointestinal and cardiovascular and renal safety]. Rev Gastroenterol Peru. 2015;35(1):63\u201371. PMID: 25875519.","journal-title":"Rev Gastroenterol Peru"},{"issue":"9","key":"771_CR34","doi-asserted-by":"publisher","first-page":"e1001098","DOI":"10.1371\/journal.pmed.1001098","volume":"8","author":"P McGettigan","year":"2011","unstructured":"McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098. https:\/\/doi.org\/10.1371\/journal.pmed.1001098.","journal-title":"PLoS Med"},{"issue":"2","key":"771_CR35","doi-asserted-by":"publisher","first-page":"e1001388","DOI":"10.1371\/journal.pmed.1001388","volume":"10","author":"P McGettigan","year":"2013","unstructured":"McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-. middle-. And high-income countries. PLoS Med. 2013;10(2):e1001388. https:\/\/doi.org\/10.1371\/journal.pmed.1001388.","journal-title":"PLoS Med"},{"key":"771_CR36","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1096\/fj.06-8061com","volume":"21","author":"B Hinz","year":"2007","unstructured":"Hinz B, et al. Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. FASEB J 2007;21:2343\u201351. https:\/\/doi.org\/10.1096\/fj.06-8061com.","journal-title":"FASEB Journal: Official Publication Federation Am Soc Experimental Biology vol"},{"key":"771_CR37","doi-asserted-by":"publisher","unstructured":"Blaser LS et al. Sep. Comparative Effects of Metamizole (Dipyrone) and Naproxen on Renal Function and Prostacyclin Synthesis in Salt-Depleted Healthy Subjects - A Randomized Controlled Parallel Group Study. Front Pharmacol 2021;12:620635. https:\/\/doi.org\/10.3389\/fphar.2021.620635","DOI":"10.3389\/fphar.2021.620635"},{"issue":"10","key":"771_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/EJA.0000000000000627","volume":"34","author":"T Stueber","year":"2017","unstructured":"Stueber T, Buessecker L, Leffler A, Gillmann Stueber HJ. The use of dipyrone in the ICU is associated with acute kidney injury: a retrospective cohort analysis. Eur J Anaesthesiol vol. 2017;34(10):673\u201380. https:\/\/doi.org\/10.1097\/EJA.0000000000000627.","journal-title":"Eur J Anaesthesiol vol"},{"issue":"2","key":"771_CR39","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.clinthera.2017.12.011","volume":"40","author":"C Pontes","year":"2018","unstructured":"Pontes C, Marsal JR, Elorza JM, Arag\u00f3n M, Prieto-Alhambra D, Morros R. Analgesic use and risk for Acute coronary events in patients with osteoarthritis: a population-based, nested case-control study. Clin Ther. 2018;40(2):270\u201383. https:\/\/doi.org\/10.1016\/j.clinthera.2017.12.011.","journal-title":"Clin Ther"},{"key":"771_CR40","doi-asserted-by":"publisher","unstructured":"Palmer SC, Di Micco L, Razavian M, Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2013;(2):CD008834. https:\/\/doi.org\/10.1002\/14651858.CD008834.pub2","DOI":"10.1002\/14651858.CD008834.pub2"},{"key":"771_CR41","doi-asserted-by":"publisher","unstructured":"Su X, Yan B, Wang L, Lv J, Cheng H, Chen Y. Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2019;20(1):309. https:\/\/doi.org\/10.1186\/s12882-019-1499-3","DOI":"10.1186\/s12882-019-1499-3"},{"key":"771_CR42","doi-asserted-by":"crossref","unstructured":"Poley A, Ortega JA, Medregal M, Mart\u00edn M, Hermosilla C, Mora F. Prevalencia de enfermedades osteoarticulares y consumo de recursos. Calidad de vida y dependencia en pacientes con artrosis. Semergen. 2011;37(9):462\u2013467. https:\/\/www.elsevier.es\/es-revista-medicina-familia-semergen-40-articulo-prevalencia-enfermedades-osteoarticulares-consumo-recursos--S113835931100147X. Accessed 25 November 2022.","DOI":"10.1016\/j.semerg.2011.03.006"},{"key":"771_CR43","unstructured":"Utilizaci\u00f3n de antiinflamatorios no esteroides (AINE) en Espa\u00f1a. 1992\u20132006. Agencia espa\u00f1ola de medicamentos y productos sanitarios 2014. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/observatorio\/docs\/AINE.pdf. Accessed 25 November 2022."},{"key":"771_CR44","unstructured":"Utilizaci\u00f3n de medicamentos antiinflamatorios no esteroideos en Espa\u00f1a durante el periodo 2013\u20132016. Agencia espa\u00f1ola de medicamentos y productos sanitarios 2017. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/observatorio\/docs\/antiinflamatorios-AINEs-periodo-2013-2016.pdf. Accessed 25 November 2022."}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00771-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T10:06:31Z","timestamp":1724839591000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00771-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00771-5","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"1 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee for Clinical Research of IDIAP Jordi Gol (reference no. P14\/072). Exemption of informed consent was considered from the participating individuals and the study was based on pseudonymized data according on data protection law.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}